Search results
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 6 days agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 6 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 2 days agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 3 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 4 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
CNBC· 24 hours agoPatients with musculoskeletal conditions who like to stay in their pajamas received some welcome...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 4 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 6 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...